Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H30N7OS.K |
| Molecular Weight | 539.737 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4
InChI
InChIKey=OCKQGXSJNJCCDO-UHFFFAOYSA-N
InChI=1S/C27H30N7OS.K/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26;/h7-10,12-15H,5-6,11,16-17H2,1-4H3;/q-1;+1
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23811571, http://www.boryung.co.kr/eng/product/mainProduct.do
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23811571, http://www.boryung.co.kr/eng/product/mainProduct.do
Fimasartan is a angiotensin II receptor antagonist which was developed in Korea for the treatment of hypertension. The drug is available in different forms: Kanarb, Dukarb (in combination with Amlodipine), Tuvero (in combination with Rosuvastatin). Fimasartan was tested to be effective in Mexican and Russian population and now is being tested in the USA.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. | 2011 Jun |
|
| Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. | 2011 Nov |
|
| Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. | 2012 Mar |
Patents
Sample Use Guides
Fimasartan is taken as a single oral dose of 60-mg tablet or a single 30-mg intravenous (IV) infusion.
Route of Administration:
Other
Rabbit thoracic aorta cells were incubated with different concentrations of fimasartan ((0.1, 1, 10 nM). At those concentrations fimasartan caused nonparallel rightward shifts in the concentration–contractile response curve to Ang II with a significant reduction in the maximal contractile response to 96.6, 47 and 18%, respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
T2ICP7GBBN
Created by
admin on Sat Dec 16 10:50:37 GMT 2023 , Edited by admin on Sat Dec 16 10:50:37 GMT 2023
|
PRIMARY | |||
|
100000168911
Created by
admin on Sat Dec 16 10:50:37 GMT 2023 , Edited by admin on Sat Dec 16 10:50:37 GMT 2023
|
PRIMARY | |||
|
71465067
Created by
admin on Sat Dec 16 10:50:37 GMT 2023 , Edited by admin on Sat Dec 16 10:50:37 GMT 2023
|
PRIMARY | |||
|
1402813-38-0
Created by
admin on Sat Dec 16 10:50:37 GMT 2023 , Edited by admin on Sat Dec 16 10:50:37 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
